# NK521 in the Treatment of Advanced Solid Tumors

> **NCT07657416** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Base Therapeutics (Shanghai) Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Ovarian Cancer
- Malignant Ascites

## Interventions

- **BIOLOGICAL:** NK521 Cell Injection
- **BIOLOGICAL:** NK521 Cell Injection

## Key facts

- **NCT ID:** NCT07657416
- **Lead sponsor:** Base Therapeutics (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01
- **Primary completion:** 2028-06
- **Final completion:** 2028-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07657416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07657416, "NK521 in the Treatment of Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07657416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*